
TY  - JOUR
AU  - Anchi, Pratibha
AU  - Khurana, Amit
AU  - Bale, Swarna
AU  - Godugu, Chandraiah
C8  - PTR-16-1468.R2
TI  - The Role of Plant-derived Products in Pancreatitis: Experimental and Clinical Evidence
JO  - Phytotherapy Research
JA  - Phytother. Res.
VL  - 31
IS  - 4
SN  - 0951-418X
UR  - https://doi.org/10.1002/ptr.5792
DO  - doi:10.1002/ptr.5792
SP  - 591
EP  - 623
KW  - pancreatitis
KW  - phytomedicine
KW  - cerulein
KW  - oxidative stress
KW  - inflammation
PY  - 2017
AB  - Pancreatitis is a gastrointestinal disease with a worldwide sharp surge during the past decade. Pancreatitis includes acute and chronic subtypes, which are graded based on the amount of pancreatic inflammation. Phytoconstituents represent a promising class of therapeutic agents with wide acceptability not only based on folk practices but sound presence of pharmacological and molecular evidences. Growing research evidence indicates that different molecular mechanisms are involved in their protective effect. Many phytoremedies have been tried for the treatment of pancreatic injuries and have shown success in preclinical animal models of pancreatitis. The literature was largely collected through PubMed and Google scholar database. A large proportion of phytochemicals targets the inflammatory cascade and modulates the overtly acting redox balance among which nuclear factor kappa-light-chain-enhancer of activated B cells is the key molecule. Inhibition of apoptosis (artemisinin, embelin), inflammasome (withaferin A), neutrophil rolling (fucoidan), Ca+2 release (caffeine), mitogen activated protein kinase (guggulsterone) and many other novel mechanisms apart from antioxidant effect have been postulated behind the protective effect of phytoconstituents. The present review deals to fill the gap of hitherto unavailable comprehensive review on various plant products screened for the treatment of pancreatitis. The possible mechanistic profile of these phytochemicals is summarized. Copyright ? 2017 John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - Vox Sanguinis
VL  - 103
IS  - s1
SN  - 0042-9007
UR  - https://doi.org/10.1111/j.1423-0410.2012.01615_1.x
DO  - doi:10.1111/j.1423-0410.2012.01615_1.x
SP  - 1
EP  - 67
PY  - 2012
ER  - 

TY  - JOUR
TI  - Proceedings of the Annual Scientific Meeting of the Thoracic Society of Australia and New Zealand
JO  - Australian and New Zealand Journal of Medicine
VL  - 24
IS  - 4
SN  - 0004-8291
UR  - https://doi.org/10.1111/j.1445-5994.1994.tb01484.x
DO  - doi:10.1111/j.1445-5994.1994.tb01484.x
SP  - 433
EP  - 489
PY  - 1994
ER  - 

AU  - Dutta, Anand S.
C7  - pp. 1-80
TI  - Discovery of New Medicines
SN  - 9781405180351
UR  - https://doi.org/10.1002/9781444317800.ch1
DO  - doi:10.1002/9781444317800.ch1
SP  - 1-80
KW  - discovery of new medicines
KW  - understanding disease processes and mechanisms in controlling disease
KW  - severe acute respiratory syndrome (SARS)
KW  - new infectious diseases - hepatitis C, human herpes virus-6, -7 and -8 and bird flu (H5N1 virus)
KW  - underlying causes of diseases - selective and less toxic drugs
KW  - market needs and changing disease patterns
KW  - new technology impact on drug discovery
KW  - combinatorial chemistry and high-throughput screening
KW  - enzymes and enzyme inhibitors
KW  - DNA and RNA based therapeutics
PY  - 1994
AB  - Summary This chapter contains sections titled: Introduction Market needs and changing disease patterns Medicines marketed in the years 2004?2007 Historical aspects Impact of new technology on drug discovery Examples of drug discovery Enzymes and enzyme inhibitors Protein?protein interaction inhibitors Protein antibody and vaccine therapeutics DNA and RNA based therapeutics Conclusions References
ER  - 

TY  - JOUR
TI  - 35th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF)
JO  - Experimental Dermatology
VL  - 17
IS  - 3
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1600-0625.2007.00679.x
DO  - doi:10.1111/j.1600-0625.2007.00679.x
SP  - 241
EP  - 290
PY  - 2008
ER  - 

TY  - JOUR
TI  - Poster
JO  - Transplant International
JA  - Transpl Int
VL  - 26
IS  - s1
SN  - 9781405180351
UR  - https://doi.org/10.1111/tri.12181
DO  - doi:10.1111/tri.12181
SP  - 28
EP  - 57
PY  - 2013
ER  - 

TY  - JOUR
TI  - Concurrent, Oral, Poster, and Video Sessions
JO  - Diseases of the Esophagus
JA  - Dis Esophagus
VL  - 25
IS  - S1
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1442-2050.2012.01405.x
DO  - doi:10.1111/j.1442-2050.2012.01405.x
SP  - 33A
EP  - 180A
PY  - 2012
ER  - 

TY  - JOUR
TI  - Posters
JO  - Clinical Microbiology and Infection
VL  - 13
IS  - s1
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1469-0691.2007.01733.x
DO  - doi:10.1111/j.1469-0691.2007.01733.x
SP  - S109
EP  - S608
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts and Index of Authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 17
IS  - 5
SN  - 9781405180351
UR  - https://doi.org/10.1002/j.1875-9114.1997.tb03809.x
DO  - doi:10.1002/j.1875-9114.1997.tb03809.x
SP  - 1079
EP  - 1133
PY  - 1997
ER  - 

TY  - JOUR
TI  - Poster Session 2, Monday 12 September
JO  - European Journal of Neurology
VL  - 18
IS  - s2
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1468-1331.2011.03552.x
DO  - doi:10.1111/j.1468-1331.2011.03552.x
SP  - 344
EP  - 620
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 42
IS  - S2
SN  - 9781405180351
UR  - https://doi.org/10.1111/acer.13833
DO  - doi:10.1111/acer.13833
SP  - 13A
EP  - 55A
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts of the 58th Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis June 27 – 30, 2012
JO  - Journal of Thrombosis and Haemostasis
JA  - J Thromb Haemost
VL  - 11
IS  - s3
SN  - 9781405180351
UR  - https://doi.org/10.1111/jth.12443
DO  - doi:10.1111/jth.12443
SP  - 1
EP  - 105
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Session-Sunday
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 23
IS  - S2
SN  - 9781405180351
UR  - https://doi.org/10.1111/ene.13093
DO  - doi:10.1111/ene.13093
SP  - 345
EP  - 600
PY  - 2016
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Mycoses
VL  - 52
IS  - s1
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1439-0507.2009.01782.x
DO  - doi:10.1111/j.1439-0507.2009.01782.x
SP  - 29
EP  - 123
PY  - 2009
ER  - 

TY  - JOUR
TI  - 5th World Congress of the International Academy of Oral Oncology (IAOO)
JO  - Head & Neck
JA  - Head Neck
VL  - 37
IS  - S1
SN  - 9781405180351
UR  - https://doi.org/10.1002/hed.24138
DO  - doi:10.1002/hed.24138
SP  - E1
EP  - E227
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts TPS
JO  - Allergy
JA  - Allergy
VL  - 74
IS  - S106
SN  - 9781405180351
UR  - https://doi.org/10.1111/all.13961
DO  - doi:10.1111/all.13961
SP  - 376
EP  - 853
PY  - 2019
ER  - 

AU  - Seitz, Rainer
AU  - König, Herbert
AU  - Dodt, Johannes
C7  - pp. 1-39
TI  - Blood
SN  - 9783527303854
UR  - https://doi.org/10.1002/14356007.a04_201.pub2
DO  - doi:10.1002/14356007.a04_201.pub2
SP  - 1-39
PY  - 2019
AB  - Abstract The article contains sections titled: 1. Introduction 2. Composition, Physiology and Chemical Properties of Blood 2.1. Blood Cells 2.1.1. Hematopoiesis, Stem Cells 2.1.2. Red Cells, Hemoglobin 2.1.3. Leukocytes, Cytokins 2.1.4. Thrombocytes 2.2. Plasma Proteins 2.2.1. Analysis of Plasma 2.2.2. Coagulation Factors 2.2.3. Fibrinolysis System 2.2.4. Plasma Proteinase Inhibitors 2.2.5. Immunoglobulins 2.2.6. Albumin 3. Production 3.1. Blood and Plasma Donation 3.2. Substances Derived from Blood Cells 3.3. Fractionation of Plasma 3.3.1. Quality Requirements 3.3.2. Preparation of Intermediate Products 3.3.3. Purification of Plasma Proteins 3.4. Recombinant Proteins 3.5. Adverse Drug Reactions of Blood Products 3.5.1. Immunogenicity 3.5.2. Thrombogenicity 3.5.3. Transmittable Pathogens 4. Therapeutic Uses 4.1. Blood Components 4.1.1. Blood and Stem Cell Preparations 4.1.2. Fresh Frozen Plasma 4.2. Hemoglobin-Derived Oxygen Carriers 4.3. Cytokins 4.4. Coagulation Factors 4.5. Plasminogen Activators 4.6. Inhibitors 4.7. Immunoglobulins 4.8. Albumin 5. Economic Aspects Blood is a multifunctional transport medium of vital importance for the body of higher organisms. Its composition is very complex and includes various cell systems with peculiar functions, proteins, electrolytes, metabolites, and highly sophisticated mediator systems. Both cells and plasma, which can be separated by centrifugation, can be used as and further processed into medicines. Serum is the fluid remaining after coagulation of the blood. In this review, blood cell systems and plasma proteins are referred to and medicinal aspects including blood and plasma collection and processing are described. The medicines derived from blood and plasma, as well as basic research and clinical trials should keep an important place because of the medicine as a whole benefits extremely from transfusions and, in particular, hemophiliacs gain an enormous improvement of life quality and life expectancy.
ER  - 

TY  - JOUR
TI  - 2009 ASAIO-IFAO Abstracts
JO  - Artificial Organs
VL  - 33
IS  - 5
SN  - 9783527303854
UR  - https://doi.org/10.1111/j.1525-1594.2009.00832.x
DO  - doi:10.1111/j.1525-1594.2009.00832.x
SP  - A1
EP  - A44
PY  - 2009
ER  - 

TY  - JOUR
TI  - 2013 Annual Meeting Abstract Supplement
JO  - Arthritis & Rheumatism
JA  - Arthritis & Rheumatism
VL  - 65
IS  - S10
SN  - 9783527303854
UR  - https://doi.org/10.1002/art.38216
DO  - doi:10.1002/art.38216
SP  - S1
EP  - S1331
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - The Journal of Dermatology
VL  - 39
IS  - s1
SN  - 9783527303854
UR  - https://doi.org/10.1111/j.1346-8138.2012.01624.x
DO  - doi:10.1111/j.1346-8138.2012.01624.x
SP  - 53
EP  - 280
PY  - 2012
ER  - 
